期刊
JOURNAL OF CONTROLLED RELEASE
卷 361, 期 -, 页码 493-509出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2023.08.015
关键词
Mesoporous cerium oxide nanozymes; MyD88 inhibitor; ROS scavenger; Anti-inflammatory therapy; Colitis
This study presents a novel mesoporous cerium oxide nanozymes (MCN) loaded with Myeloid differentiation factor-88 (MyD88) inhibitor for synergistic treatment of ulcerative colitis. The MCN exhibits excellent ROS scavenging abilities and can carry the MyD88 inhibitor, achieving a dual therapeutic effect. Coating the MCN with dextran sulfate sodium (DSS) and enteric material Eudragit S100 enhances their anti-inflammatory abilities and colon targeting. The combination of MCN-mediated ROS scavenging and MyD88 inhibition effectively reduces inflammation in colitis mice.
Excessive reactive oxygen species (ROS) and stressed inflammatory response are major characteristics of ulcerative colitis, which cause disease progression and aggravation. Herein, a novel mesoporous cerium oxide nanozymes (MCN) was designed and then loaded with Myeloid differentiation factor-88 (MyD88) inhibitor for synergistic treatment of colitis by scavenging ROS and regulating inflammation. This innovative MCN with average particle size of 200.7 nm, specific surface area of 119.78 m2/g and mesopores of 4.47 nm not only exhibited excellent SOD-like and CAT-like activities to scavenge ROS but also could act as a carrier to load MyD88 inhibitor, TJ-M2010-5, (abbreviated as TJ-5) into their mesopores, achieving the effect of 'two birds with one stone'. Besides, the modification of dextran sulfate sodium (TJ-5/MCN/DSS) increased the internalization of nanozymes into activated macrophages and enhanced in vitro anti-inflammatory ability. To enhance colon targeting, we coated TJ-5/MCN/DSS with the enteric material Eudragit S100, preventing premature release or absorption of the drug in the gastrointestinal tract after oral administration. The results demonstrated that TJ-5/ MCN/DSS/Eudragit not only achieved delayed drug release and improved colon targeting but also exhibited optimal therapeutic efficacy in colitis mice. Mechanistically, the MCN-mediated ROS scavenging and TJ-5mediated MyD88 blockade synergistically inhibited the NF-& kappa;B signaling pathway, thereby reducing the inflammatory response. Importantly, TJ-5/MCN/DSS/Eudragit did not induce systemic toxicity. In conclusion, our work not only presents a novel carrier capable of scavenging ROS but also provides proof of concept for the synergistic treatment of colitis using this carrier in combination with MyD88 inhibitors. This study proposes a safe and efficient strategy for targeting ROS-associated inflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据